With immunohistochemical analyses being limited to post-mortem IDH-mutant glioma, and conventional magnetic resonance imaging (MRI) incapable of delineating diffuse tumor cell migration, the extent of occult tumor cell burden has not been determined in vivo, although it might offer prognostically valuable information. The gene discussed is IDH2; the disease is glioma.